Human FOLR2 Protein, His Tag
分子別名(Synonym)
FOLR2,BETA-HFR,FBP,PL-1,FR-BETA,FR-P3,FBP
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human FOLR2, His Tag (FO2-H5223) is expressed from human 293 cells (HEK293). It contains AA Thr 17 - His 228 (Accession # P14207-1).
Predicted N-terminus: Thr 17
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.5 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to N-linked glycosylation which has been verified by PNGase F digestion.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in Tris and Glycine, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.


背景(Background)
葉酸受體β也稱為葉酸受體2、FBP、FOLR2、beta-HFR、FBP/PL-1、FR-beta、FR-P3,是葉酸受體(FOLR)家族的成員。并介導(dǎo)5-甲基四氫葉酸向細(xì)胞內(nèi)部的遞送。該蛋白分別與FOLR1和FOLR3蛋白具有68%和79%的序列同源性。FOLR2蛋白最初被認(rèn)為只存在于胎盤中,但也在脾臟、骨髓和胸腺中檢測(cè)到。FOLR2主要在胎盤、中性粒細(xì)胞譜系細(xì)胞和一些CD34+造血祖細(xì)胞中表達(dá)。它在髓系白血病、頭頸部鱗狀細(xì)胞癌和幾種非上皮性癌癥中上調(diào)。它也在慢性炎癥部位的巨噬細(xì)胞和單核細(xì)胞上上調(diào),包括類風(fēng)濕性關(guān)節(jié)炎滑膜和膠質(zhì)母細(xì)胞瘤。FOLR2是M-CSF存在下產(chǎn)生的巨噬細(xì)胞的標(biāo)志物,但不是GM-CSF。其表達(dá)與葉酸攝取能力的增強(qiáng)有關(guān)。治療藥物的葉酸偶聯(lián)物是靶向腫瘤相關(guān)巨噬細(xì)胞的潛在免疫治療工具。
關(guān)鍵字: FOLR2;FOLR2蛋白;FOLR2重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。